We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Neurodegenerative Disease Fueled by "Leaky" Mutated Protein

Neurodegenerative Disease Fueled by "Leaky" Mutated Protein content piece image
Patients with spinocerebellar ataxia type 14 display cerebellar atrophy (right, green arrow) compared to age-matched healthy controls (left). Credit: UC San Diego Health Sciences
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Spinocerebellar ataxias are a group of neurodegenerative diseases characterized by the degeneration of Purkinje cells, a major class of neurons in the cerebellum. The resulting cerebellar dysfunction leads patients to experience a loss of motor coordination and control.

One subtype of the disease, spinocerebellar ataxia type 14 (SCA14), was found to be caused by mutations in protein kinase C-gamma (PKCγ), an enzyme that regulates other proteins in Purkinje cells. But exactly how these mutations alter the enzyme’s function to ultimately drive neurodegeneration remained unknown.

In a new study, published September 27, 2022 in Science Signaling, researchers at University of California San Diego School of Medicine found that SCA14-associated mutations disrupt the autoinhibition and degradation of PKCγ, leading to elevated levels of enzyme activity. This sustained “leaky” activity alters the Purkinje cell phosphoproteome to drive cerebellar pathology.

“Our findings reveal important mechanisms underlying spinocerebellar ataxia and position PKCγ as a promising therapeutic target for this neurodegenerative disease,” said senior author Alexandra C. Newton, PhD, Distinguished Professor of Pharmacology at UC San Diego School of Medicine.

To understand how the SCA14-associated mutations affect the enzyme’s function, researchers first measured activity levels of different PKCγ variants in cultured cells. Compared to more common PKCγ variants, those with SCA14 mutations in the protein’s C1A and C1B domains showed significantly enhanced enzymatic activity, which further experiments confirmed was due to conformational changes that impair the enzyme’s autoinhibition and degradation.

Autoinhibition is an on-site regulatory mechanism in which certain domains within a molecule’s structure act to repress its own function.

Researchers then found the enhanced PKCγ activity led to a cascade of downstream changes to the phosphorylation state of the cellular environment, particularly dysregulating signaling pathways involved in axon development and cytoskeletal structure.

The extent of disrupted PKCγ autoinhibition correlated with disease severity, and mutations that induced a particularly high level of PKCγ activity were also associated with an earlier age of disease onset.

PKCγ is itself regulated by intracellular calcium, and many other types of spinocerebellar ataxia are driven by mutations that affect calcium homeostasis. Thus, the authors suggest that targeting PKCγ may correct this broader signaling pathway and prove effective in treating multiple forms of the disease.

“This raises exciting possibilities for therapeutically targeting PKCγ not only in SCA14 but also in many other subtypes of spinocerebellar ataxia,” Newton said.

Reference: Pilo CA, Baffi TR, Kornev AP, et al. Mutations in protein kinase Cγ promote spinocerebellar ataxia type 14 by impairing kinase autoinhibition. Sci Signal. 2022;15(753):eabk1147. doi: 10.1126/scisignal.abk1147


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.